IMMX Stock Analysis: Immix Biopharma | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 736m USD | 12M Return: 358.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 16.2M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 4.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Immix Biopharma, Inc. (NASDAQ: IMMX) is a U.S.-based, clinical-stage biopharmaceutical company developing chimeric antigen receptor (CAR) cell therapies, with its lead candidate NXC-201 targeting relapsed/refractory AL amyloidosis and immune-mediated diseases across the United States and Australia. Incorporated in 2012 and headquartered in Los Angeles, California, the company went public on December 16, 2021, and is classified within the Health Care sector, specifically the Biotechnology sub-industry, with a small-cap market valuation of approximately $621M USD.
As a clinical-stage biopharma, Immix has not yet commercialized a product and primarily generates value through pipeline advancement and R&D milestones. CAR-T cell therapy, the companys core modality, involves engineering a patients own T cells to recognize and attack disease-associated antigens, an approach that has seen growing investment in rare hematologic and autoimmune indications such as AL amyloidosis, where abnormal antibody light chains accumulate in organs.
- NXC-201 Phase 1/2 data readouts for AL Amyloidosis
- FDA orphan drug and fast track designations accelerate NXC-201 development
- Capital raises and ATM offerings dilute shareholders amid clinical-stage cash burn
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.34 > 0.02 and ΔFCF/TA 33.15 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.33 > 3% & CFO -32.1m > Net Income -35.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (38.3m) vs 12m ago 28.90% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.48%; Δ -0.48% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.85 (Total Current Assets 92.3m - Total Current Liabilities 10.5m) / Total Assets 95.8m |
| B: -1.20 (Retained Earnings -114.5m / Total Assets 95.8m) |
| C: -0.60 (EBIT TTM -35.0m / Avg Total Assets 57.9m) |
| D: 7.37 (Book Value of Equity 84.4m / Total Liabilities 11.5m) |
| Altman-Z'' = 5.37 = AAA |
As of July 08, 2026, the stock is trading at USD 12.02 with a total of 4,237,681 shares traded. Over the past week, the price has changed by +14.59%, over one month by +52.73%, over three months by +32.23% and over the past year by +358.78%.
Current recommended Stop Loss: 11.10 (which is 7.7% or 1.2 ATR below the current price).
Immix Biopharma has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy IMMX.
- StrongBuy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 19.8 | 64.3% |
P/B = 8.7253
Revenue TTM = 0.0 USD
EBIT TTM = -35.0m USD
EBITDA TTM = -34.6m USD
Long Term Debt = 912k USD (estimated: total debt 1.04m - short term 125k)
Short Term Debt = 125k USD (from shortTermDebt, last quarter)
Debt = 1.04m USD (from shortLongTermDebtTotal, last quarter) (leases 1.04m already included)
Net Debt = -89.5m USD (calculated: Debt 1.04m - CCE 90.6m)
Enterprise Value = 646.6m USD (736.1m + Debt 1.04m - CCE 90.6m)
Interest Coverage Ratio = unknown (Ebit TTM -35.0m / Interest Expense TTM 0.0)
EV/FCF = -19.73x (Enterprise Value 646.6m / FCF TTM -32.8m)
FCF Yield = -5.07% (FCF TTM -32.8m / Enterprise Value 646.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 365k) / Revenue TTM)
Tobins Q-Ratio = 6.75 (Enterprise Value 646.6m / Total Assets 95.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.04m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -27.6m (EBIT -35.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.76 (Total Current Assets 92.3m / Total Current Liabilities 10.5m)
Debt / Equity = 0.01 (Debt 1.04m / totalStockholderEquity, last quarter 84.4m)
Debt / EBITDA = 2.59 (negative EBITDA) (Net Debt -89.5m / EBITDA -34.6m)
Debt / FCF = 2.73 (negative FCF - burning cash) (Net Debt -89.5m / FCF TTM -32.8m)
Total Stockholder Equity = 47.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -60.47% (Net Income -35.0m / Total Assets 95.8m)
RoE = -73.23% (Net Income TTM -35.0m / Total Stockholder Equity 47.8m)
RoCE = -71.80% (EBIT -35.0m / Capital Employed (Equity 47.8m + L.T.Debt 912k))
RoIC = -32.33% (negative operating profit) (NOPAT -27.6m / Invested Capital 85.4m)
WACC = 10.72% (E(736.1m)/V(737.1m) * Re(10.74%) + D(1.04m)/V(737.1m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.74% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 89.89 | Cagr: 33.69%
[DCF] Fair Price = unknown (Cash Flow -32.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.38 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.17 | Chg30d=+14.15% | Revisions=+29% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.17 | Chg30d=+15.54% | Revisions=+17% | Analysts=6
EPS current Year (2026-12-31): EPS=-0.69 | Chg30d=+12.48% | Revisions=+29% | GrowthEPS=+22.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.74 | Chg30d=-4.46% | Revisions=-17% | GrowthEPS=-7.3% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +24% (up=9, down=5)